Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

NMRA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $8K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $5.01M.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $8K or moves back toward the trailing-twelve-month quarterly average of $1.25M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8K— QoQ
Last fiscal yearDec 2025
$5M— YoY
LTMMar 2026
$5.01M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
5M USD
Year-over-year change
—

Cost of Revenue vs competitors

How NMRA compares with its peers on the latest reported figures

  • NMRA's LTM Mar 2026 cost of revenue of $5.01M is the 7th highest of the 10 companies compared; the peer median is $11.12M.
NMRA Competitors Peer median
Cost of Revenue for NMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$102.95M -34.6%—111.2%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$99.22M -12.1%-54.4%112.4%
BCYCBicycle Therapeutics plcLTM Mar 2026$71.03M -55.3%—111.9%
PRTAProthena Corporation plcLTM Mar 2026$30.8M ——53.2%
OMEROmeros CorporationLTM Mar 2026$11.12M +3594.0%—112.4%
ADCTADC Therapeutics S.A.LTM Mar 2026$7.35M +33.7%+32.5%9.3%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$5.01M ———
ALMSAlumis Inc. Common StockLTM Jun 2026$871K +6.2%+140.9%11.8%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$646K -97.5%-82.7%0.9%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$338K -99.3%-73.7%—
Peer median (excluding NMRA) $11.12M-23.3%-54.4%82.2%

Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00668K05M
Gross Profit00(668K)0(5M)
Gross Margin—————
Research & Development212.78M104.75M142.72M200.93M176.07M
Selling, General & Admin24.55M31.12M44.81M62.54M60.09M
Operating Expenses237.32M135.87M187.53M263.46M236.16M
Depreciation & Amortization538K594K668K631K208K
EBITDA(236.77M)(130.31M)(234.99M)(242.98M)(233.37M)
EBITDA Margin—————
Operating Income(237.32M)(135.87M)(188.19M)(263.46M)(241.16M)
Operating Margin—————
Interest Income04.56M16.61M19.93M8.34M
Interest Expense00003.22M
Other Income / Expenses11K4.97M(47.46M)19.86M4.36M
Income Before Tax(237.31M)(130.9M)(235.66M)(243.61M)(236.8M)
Pre-Tax Margin—————
Income Tax Expense00268K178K130K
Net Income(237.31M)(130.9M)(235.93M)(243.79M)(236.93M)
Net Margin—————
EPS (Basic)(1.56)(0.86)(1.49)(1.53)(1.45)
EPS (Diluted)(1.56)(0.86)(1.49)(1.53)(1.45)
Weighted Avg Shares151.95M151.95M158.83M159.38M163.39M
Weighted Avg Shares (Diluted)151.95M151.95M158.83M159.38M163.39M

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.